AR097648A1 - Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide - Google Patents

Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide

Info

Publication number
AR097648A1
AR097648A1 ARP140103413A ARP140103413A AR097648A1 AR 097648 A1 AR097648 A1 AR 097648A1 AR P140103413 A ARP140103413 A AR P140103413A AR P140103413 A ARP140103413 A AR P140103413A AR 097648 A1 AR097648 A1 AR 097648A1
Authority
AR
Argentina
Prior art keywords
epigenetic
cd33
factor
compound
selected
Prior art date
Application number
ARP140103413A
Other languages
English (en)
Inventor
Subklewe Marion
Krupka Christina
B Walter Roland
Original Assignee
Amgen Inc
Amgen Res (Munich) Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201361877714P priority Critical
Application filed by Amgen Inc, Amgen Res (Munich) Gmbh filed Critical Amgen Inc
Publication of AR097648A1 publication Critical patent/AR097648A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)

Abstract

Una combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana CD33 y CD3 en el tratamiento de leucemia mieloide, en donde el factor epigenético está seleccionado del grupo que consiste de inhibidores de histona desacetilasa (HDAC), inhibidores de ADN metiltransferasa (DNMT) I, hidroxiurea, Factor Estimulante Colonia de Granulocitos (G-CSF), inhibidores de histona desmetilasa y ATRA (ácido todo-trans-retinoico). Una composición farmacéutica que comprende un compuesto que tienen como diana CD33 y al menos un factor epigenético. Un factor epigenético para uso en la mejora y/o tratamiento de una leucemia mieloide, en donde el factor epigenético aumenta la respuesta de un paciente a un compuesto que tiene como diana CD33. Uso de al menos un factor epigenético para incrementar el grado de respuesta de un paciente con leucemia mieloide a un tratamiento con un compuesto que tiene como diana CD33, un método para el tratamiento de una leucemia mieloide, que comprende la administración de al menos un factor epigenético y un compuesto que tiene como diana CD33 a un paciente en necesidad del mismo y un kit que comprende una composición farmacéutica de la presente o un factor epigenético de la presente y un compuesto biespecífico que tiene como diana CD33. Reivindicación 1: Una composición farmacéutica que comprende un compuesto que tienen como diana CD33 y al menos un factor epigenético, en donde (a) el compuesto que tiene como diana CD33 es un constructo biespecífico que comprende un primer dominio de unión que se une específicamente a CD33 y un segundo dominio de unión que se une específicamente a CD3; y (b) el al menos un factor epigenético está seleccionado del grupo que consiste de inhibidores de histona desacetilasa (HDAC), inhibidores de ADN metiltransferasa (DNMT) I, hidroxiurea, Factor Estimulante Colonia de Granulocitos (G-CSF), inhibidores de histona metiltransferasa (HMT) y ATRA (ácido todo-trans-retinoico). Reivindicación 2: La composición farmacéutica de la reivindicación 1, en donde el al menos un factor epigenético está seleccionado del grupo que comprende (a) un inhibidor de histona desacetilasa (HDAC) seleccionado del grupo que consiste de panobinostat, vorinostat, romidepsin, N-acetildinalina, belinostat, givinostat, entinostat, mocetinostat, EVP-0334, SRT501, CUDC-101, Quisinostat, abexinostat, LAQ824, y ácido valproico; (b) un inhibidor de ADN metiltransferasa (DNMT) l seleccionado del grupo que consiste de 5-azacitidina, decitabina, hidralazina, zebularina, procainamida, (-)-epigalocatequin-3-galato, MG98, RG108, y SGI-110; y (c) un inhibidor de histona metiltransferasa (HMT) seleccionado del grupo que consiste de un inhibidor de LSD1 (KDM1A) desmetilasa, y quetocina.
ARP140103413A 2013-09-13 2014-09-12 Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide AR097648A1 (es)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US201361877714P true 2013-09-13 2013-09-13

Publications (1)

Publication Number Publication Date
AR097648A1 true AR097648A1 (es) 2016-04-06

Family

ID=51690351

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140103413A AR097648A1 (es) 2013-09-13 2014-09-12 Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide

Country Status (17)

Country Link
US (1) US20160317657A1 (es)
EP (1) EP3043794A2 (es)
JP (1) JP2016536341A (es)
KR (1) KR20160058120A (es)
CN (1) CN105764505A (es)
AP (1) AP201609132A0 (es)
AR (1) AR097648A1 (es)
AU (1) AU2014320246A1 (es)
CA (1) CA2923354A1 (es)
CL (1) CL2016000564A1 (es)
EA (1) EA201690485A1 (es)
MA (1) MA38898A1 (es)
MX (1) MX2016003197A (es)
PH (1) PH12016500434A1 (es)
SG (2) SG10201801777YA (es)
TW (1) TW201605473A (es)
WO (1) WO2015036583A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9212225B1 (en) * 2014-07-01 2015-12-15 Amphivena Therapeutics, Inc. Bispecific CD33 and CD3 binding proteins
BR112017025479A2 (pt) * 2015-05-29 2018-08-07 Amphivena Therapeutics Inc métodos para utilizar proteínas de ligação cd33 e cd3 biespecíficas
AU2016301961A1 (en) 2015-08-05 2018-01-18 Amgen Research (Munich) Gmbh Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers
EP3390653A1 (en) * 2015-12-16 2018-10-24 H. Hoffnabb-La Roche Ag Improved recombinant production method
TW201728339A (en) * 2016-01-25 2017-08-16 Amgen Res (Munich) Gmbh Pharmaceutical composition comprising bispecific antibody constructs
EA201892367A1 (ru) * 2016-04-19 2019-04-30 Эмджен Рисерч (Мюник) Гмбх Введение биспецифической конструкции, связывающейся с cd33 и cd3, для применения в способе лечения миелоидного лейкоза

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (es) 1979-07-11 1985-06-05 Ajinomoto Kk
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
EP0623679B1 (en) 1987-05-21 2003-06-25 Micromet AG Targeted multifunctional proteins
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
DK0575319T3 (da) 1991-03-11 2000-07-10 Univ Georgia Res Found Kloning og ekspression af Renilla-luciferase
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
JP3589665B2 (ja) 1992-10-23 2004-11-17 イミュネックス・コーポレーションImmunex Corporation 可溶性オリゴマー蛋白質の調製法
EP0759170B1 (en) 1993-09-10 2008-07-09 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US6458547B1 (en) 1996-12-12 2002-10-01 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
WO1999049019A2 (en) 1998-03-27 1999-09-30 Prolume, Ltd. Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics
AT244758T (de) 1998-04-21 2003-07-15 Micromet Ag Cd19xcd3 spezifische polypeptide und deren verwendung
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッドAmgen Inc. 自己緩衝タンパク質製剤
EP1940881B1 (en) 2005-10-11 2016-11-30 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
WO2008058021A2 (en) * 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
EP3461842A1 (en) 2007-04-03 2019-04-03 Amgen Research (Munich) GmbH Cross-species-specific binding domain
US9079958B2 (en) * 2010-10-04 2015-07-14 Boehringer Ingelheim International Gmbh CD33 binding agents
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
TW201605473A (en) 2016-02-16
EA201690485A1 (ru) 2016-08-31
MX2016003197A (es) 2016-06-02
MA38898A1 (fr) 2018-01-31
KR20160058120A (ko) 2016-05-24
PH12016500434A1 (en) 2016-05-16
WO2015036583A3 (en) 2015-07-02
US20160317657A1 (en) 2016-11-03
JP2016536341A (ja) 2016-11-24
AU2014320246A1 (en) 2016-02-18
WO2015036583A2 (en) 2015-03-19
CA2923354A1 (en) 2015-03-19
CL2016000564A1 (es) 2017-03-24
CN105764505A (zh) 2016-07-13
SG10201801777YA (en) 2018-04-27
SG11201600671QA (en) 2016-02-26
AP201609132A0 (en) 2016-04-30
EP3043794A2 (en) 2016-07-20

Similar Documents

Publication Publication Date Title
DOP2014000107A (es) AGENTES DE iARN, COMPOSICIONES Y MÉTODOS DE USO DE LOS MISMOS PARA TRATAR ENFERMEDADES ASOCIADAS CON TRANSTIRETINA (TTR)
CL2015002522A1 (es) Composiciones y métodos para activar "estimulador de interferon gene" - señalización dependientes.
BR112013009708A2 (pt) aparelhos, métodos e composições para tratamento endodôntico
DOP2013000104A (es) Antagonistas de mdm2 de espiro-oxindol
CL2007001602A1 (es) Uso de un inhibidor de dimerizacion del receptor her para tratar cancer que produce altos niveles del factor de crecimiento epidermico (egf) o del factor de crecimiento transformador alfa (tgf-alfa).
MX344530B (es) Compuestos de benceno substituido.
ES2670983T3 (es) Métodos y composiciones relacionados con CRISPR con ARNg rectores
ECSP11010798A (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
BRPI1012781A2 (pt) n-[(2'r)-2'-deóxi-2'-fluor-2'-metil-p-fenil-5'-uridil]-l-alanina 1-metiletil éster e processo para sua produção
ECSP11011297A (es) Proteinas ligadoras il-17
EA201591599A1 (xx) Ингибиторы ido
SG194447A1 (en) Aryl-or heteroaryl-substituted benzene compounds
CL2011001497A1 (es) Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico.
BR112017007647A2 (pt) cartucho de grampos
BRPI0920272A2 (pt) composição de filtro-solar, método para melhorar a resistência à água de uma composição de filtro-solar, método para melhorar a eficácia de filtro-solar, e, formulação de filtro-solar
CL2012002026A1 (es) Compuestos derivados de amidas, inhibidores de hdac6; composicion farmaceutica que los comprende; kit farmaceutico;utiles en el tratamiento del cancer, artritis reumatoide, colitis ulcerativa, enfermedad de crohn, lupus eritematoso,sistemico, entre otras.
BR112013026494A2 (pt) composto, composição farmacêutica, método para tratar condição
CR20140388A (es) Compuestos terapeuticamente activos y sus métodos de uso
BR112015016005A2 (pt) preparação de amostra em um suporte sólido
CR9664A (es) Inhibidores de histona deacetilasa
BR112015022588A2 (pt) composto, composição farmacêutica, e, método para tratamento de imunossupressão em um indivíduo
BRPI1011738A2 (pt) composições de revestimento de semente e métodos para aplicações de tensoativos ao solo para impermeabilização do mesmo
BR112014013661A2 (pt) derivados de nucleosídeos 2’,4’-difluoro-2’-metil substituídos como inibidores de replicação de hcv-rna
UA119136C2 (uk) Заміщені фенілкарбоксамідні сполуки
CO6321188A2 (es) Tratamiento de cancer con combinaciones de inhibidores de la topoisomerasa e inhibidores de parp